The global market for Imaging Agents was estimated at US$10.3 Billion in 2024 and is projected to reach US$13.4 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Imaging Agents market.
Technological progress in medical imaging continues to expand possibilities, leading to faster, safer, and more efficient imaging. Companies leverage advanced technology and globally accepted safety protocols to offer comprehensive imaging solutions. Key drivers in imaging advancements include AI, machine learning, and deep learning. These technologies are integrated into CT scans, MRIs, and ultrasounds to automate repetitive tasks with nearly perfect accuracy, cutting costs compared to traditional methods. Healthcare professionals increasingly rely on AI-based solutions to assess risk and tailor treatments, ensuring optimal, cost-effective therapy. Virtual and augmented reality (VR/AR) in 3D medical imaging technologies provide physicians with enhanced visualization of complex structures by creating 3D images from 2D MRI or CT scans. While the VR/AR market is still developing, its transformative potential in healthcare is becoming evident.
Nuclear imaging and wearable technology are also driving advancements in medical imaging. Nuclear imaging uses radiotracers to provide detailed insights into internal conditions such as cancer and Alzheimer`s disease, with devices like the EXPLORER Total-body PET/CT Scanner improving efficiency. Wearables offer new applications in radiology, with the HD-DOT instrument and wearable ultrasound scanners enabling continuous brain and organ monitoring. These innovations are expanding diagnostic capabilities and improving patient care by providing earlier detection and more effective treatments.
Global Imaging Agents Market - Key Trends and Drivers Summarized
Diagnostic imaging agents, or contrast agents, are substances administered to patients to enhance the imaging process for disease diagnosis. These agents help radiopharmaceuticals emit energy using various methods, such as X-rays, gamma rays, sound waves, radio waves (MRI), and radioactive particles. By improving image contrast, they enable healthcare professionals to better visualize and assess body structures and detect abnormalities, providing critical insights for accurate diagnosis. Medical imaging is a critical tool that saves millions of lives by helping doctors diagnose diseases ranging from cancer to stroke. One of the most influential trends shaping this field is artificial intelligence (AI).Technological progress in medical imaging continues to expand possibilities, leading to faster, safer, and more efficient imaging. Companies leverage advanced technology and globally accepted safety protocols to offer comprehensive imaging solutions. Key drivers in imaging advancements include AI, machine learning, and deep learning. These technologies are integrated into CT scans, MRIs, and ultrasounds to automate repetitive tasks with nearly perfect accuracy, cutting costs compared to traditional methods. Healthcare professionals increasingly rely on AI-based solutions to assess risk and tailor treatments, ensuring optimal, cost-effective therapy. Virtual and augmented reality (VR/AR) in 3D medical imaging technologies provide physicians with enhanced visualization of complex structures by creating 3D images from 2D MRI or CT scans. While the VR/AR market is still developing, its transformative potential in healthcare is becoming evident.
Nuclear imaging and wearable technology are also driving advancements in medical imaging. Nuclear imaging uses radiotracers to provide detailed insights into internal conditions such as cancer and Alzheimer`s disease, with devices like the EXPLORER Total-body PET/CT Scanner improving efficiency. Wearables offer new applications in radiology, with the HD-DOT instrument and wearable ultrasound scanners enabling continuous brain and organ monitoring. These innovations are expanding diagnostic capabilities and improving patient care by providing earlier detection and more effective treatments.
SCOPE OF STUDY:
The report analyzes the Imaging Agents market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product Segment (Diagnostic Radiopharmaceuticals, X-Ray / CT, MRI, Ultrasound)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Diagnostic Radiopharmaceuticals segment, which is expected to reach US$7.2 Billion by 2030 with a CAGR of a 5.8%. The X-Ray / CT segment is also set to grow at 3.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $2.7 Billion in 2024, and China, forecasted to grow at an impressive 7.9% CAGR to reach $2.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Imaging Agents Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Imaging Agents Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Imaging Agents Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Aytu BioScience Inc., Bayer Healthcare Pharmaceuticals, Bracco Diagnostics Inc., Curium, Daiichi Sankyo Company Limited and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 23 companies featured in this Imaging Agents market report include:
- Aytu BioScience Inc.
- Bayer Healthcare Pharmaceuticals
- Bracco Diagnostics Inc.
- Curium
- Daiichi Sankyo Company Limited
- Eli Lilly
- GE Healthcare
- Guerbet Group
- Lantheus Medical Imaging Inc.
- Piramal Imaging SA
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aytu BioScience Inc.
- Bayer Healthcare Pharmaceuticals
- Bracco Diagnostics Inc.
- Curium
- Daiichi Sankyo Company Limited
- Eli Lilly
- GE Healthcare
- Guerbet Group
- Lantheus Medical Imaging Inc.
- Piramal Imaging SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 184 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 10.3 Billion |
| Forecasted Market Value ( USD | $ 13.4 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
